Look Over Your Shoulder, Roche: Abbott’s Coming Up Behind
Abbott Labs’ proposed $5.8bn acquisition of Alere will give its IVD sales a significant boost and propel the company up the ranks to become the sector’s No. 2, behind Roche.
Abbott Labs’ proposed $5.8bn acquisition of Alere will give its IVD sales a significant boost and propel the company up the ranks to become the sector’s No. 2, behind Roche.